J Neurol Neurosurg Psychiatry 73:629-635 doi:10.1136/jnnp.73.6.629
  • Paper

The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease

  1. K R Chaudhuri1,
  2. S Pal1,
  3. A DiMarco3,
  4. C Whately-Smith8,
  5. K Bridgman6,
  6. R Mathew3,
  7. F R Pezzela5,
  8. A Forbes2,
  9. B Högl7,
  10. C Trenkwalder4
  1. 1Department of Neurology, King’s College Hospital, London SE5, UK
  2. 2University Hospital Lewisham, London, UK
  3. 3Guy’s, King’s and St Thomas’ School of Medicine, King’s College, London, UK
  4. 4Department of Clinical Neurophysiology, University of Göttingen, Germany
  5. 5Department of Neurological Science, University of Rome La Sapienza, Rome, Italy
  6. 6Pharmacia Limited, Milton Keynes, UK
  7. 7Max-Planck Institute of Psychiatry, Munich, Germany
  8. 8Independent statistician
  1. Correspondence to:
 Dr K R Chaudhuri, Department of Neurology, King’s College Hospital, Denmark Hill, London, SE5 9RS;
  • Received 30 April 2002
  • Accepted 20 August 2002
  • Revised 19 July 2002


Background: No formal instruments are available for quantifying sleep problems in Parkinson’s disease.

Objective: To develop a new sleep scale to quantify the various aspects of nocturnal sleep problems in Parkinson’s disease, which may occur in up to 96% of affected individuals.

Methods: Employing a multidisciplinary team approach, a visual analogue scale was devised addressing 15 commonly reported symptoms associated with sleep disturbance in Parkinson’s disease—the Parkinson’s disease sleep scale (PDSS). In all, 143 patients with Parkinson’s disease completed the PDSS, covering the entire spectrum of disease from newly diagnosed to advanced stage. As controls, 137 age healthy matched subjects also completed the scale. Test–retest reliability was assessed in a subgroup of subjects. The Epworth sleepiness scale was also satisfactorily completed by 103 of the patients with Parkinson’s disease.

Results: PDSS scores in the Parkinson group were significantly different from the healthy controls. Patients with advanced Parkinson’s disease had impaired scores compared with early/moderate disease. Individual items of the scale showed good discriminatory power between Parkinson’s disease and healthy controls. Relevant items of the PDSS correlated with excessive daytime sleepiness. The scale showed robust test–retest reliability.

Conclusions: This appears to be the first description of a simple bedside screening instrument for evaluation of sleep disturbances in Parkinson’s disease. A combination of subitems may help identify specific aspects of sleep disturbance, which in turn may help target treatment.


  • Competing interests: C W-S has previously undertaken statistical analysis and consulting work for Pharmacia Ltd. CT has used the PDSS scale within a treatment study has been supported by a research grant of Pharmacia. KB is an employee of Pharmacia Ltd. KRC has received honorarium from Pharmacia and Orion pharmaceuticals for presentation of data related to PDSS in the UK and abroad.

Visit the full archive of podcasts for JNNP here >>

Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JNNP.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article